Cabergoline 0.5 MG
Cabergoline 0.5 MG is a pharmaceutical drug with 7 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 3 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
3
Mid Stage
1
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
100.0%
3 of 3 finished
0.0%
0 ended early
2
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Viaca (Sildenafil + Cabergoline) Compared With Sildenafil and Cabergoline
Cabergoline for the Treatment of Chronic Pain Due to Endometriosis
Cabergoline & Letrozole Versus Letrozole in Ovulation Induction in PCOS
Cabergoline for Episodic Migraine
Cabergoline in the Management of Nonfunctioning Pituitary Adenoma
Clinical Trials (7)
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Viaca (Sildenafil + Cabergoline) Compared With Sildenafil and Cabergoline
Cabergoline for the Treatment of Chronic Pain Due to Endometriosis
Cabergoline & Letrozole Versus Letrozole in Ovulation Induction in PCOS
Cabergoline for Episodic Migraine
Cabergoline in the Management of Nonfunctioning Pituitary Adenoma
Cabergoline as a Preventive Treatment for Chronic Migraine
Effects of Combined Metformin and Cabergoline in Comparison With Metformin Only Therapy on Ovarian and Hormonal Activities in Iraqi Patients With PCOS
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7